



U.S. DEPARTMENT OF JUSTICE ★ DRUG ENFORCEMENT ADMINISTRATION

DIVERSION CONTROL DIVISION

Vulnerabilities with Veterinary Medicines - September 28, 2021

Vulnerabilities with Veterinary Medicines Increase the Risk of Use in Criminal Activity

To whom it may concern,

The DEA's Diversion Control Division and the FBI's Weapons of Mass Destruction Directorate are disseminating the attached FBI Liaison Information Report, "[Increased Xylazine Abuse Presents Potential for Weaponization; Exacerbates Limited Medical Countermeasures](#)" to all DEA-registered veterinarians to build awareness and familiarity with this particular concern.

The DEA and FBI believe this is worthwhile information for the veterinary community's consumption and to highlight a potential vulnerability. Within the last decade, the veterinary sedative xylazine has increasingly been used as an adulterant in illicit drug production and has led to overdoses and deaths in multiple US states. While opioids and other controlled substances receive a majority of media coverage and attention, other non-controlled substances, like xylazine, may be abused or used for otherwise nefarious purposes, including weaponization.

Furthermore, an LIR previously disseminated to the veterinary community in 2020, "[Vulnerabilities with Veterinary Medicines Increase the Risk of Use in Criminal Activity,](#)" is being reshared for additional awareness.

The DEA and FBI request this Liaison Information Report remain solely in the hands of the veterinary community and not be further disseminated.

Should you have any questions or concerns, please reach out to your local FBI Weapons of Mass Destruction Coordinator and/or FBI Private Sector Coordinator at your local FBI Field Office: <https://www.fbi.gov/contact-us/field-offices>.

Should you have any questions or concerns regarding controlled substances, please reach out to DEA's Pharmaceutical Investigations Section at 571-632-1720.